11/25/2023 0 Comments Dato dxdAnd you have recovered from the side effects apart from certain ones. If you had immunotherapy you must not have stopped treatment due to the side effects. have already had durvalumab and certain targeted treatments.This is apart from certain ones which your doctor will know about. have ongoing side effects from previous treatments.Or you have a type of NSCLC called sarcomatoid carcinoma. have cancer that is a mix of small cell lung cancer and NSCLC.Or there is no record of certain gene changes in your medical notes. have NSCLC that has certain gene changes ( mutations ) in the cancer cells.have or had cancer spread to the tissues surrounding the brain.This is unless there are no symptoms, it is stable and you have not had steroids for 7 days before starting treatment. have cancer spread to your brain or you have spinal cord compression.have already had treatment for your advanced NSCLC.You cannot join this trial if any of these apply. You are willing to use contraception during treatment and for a certain time after if there is any chance you or your partner could become pregnant.You are able to look after yourself but might not be able to do heavy physical work ( performance status 0 or 1).You have at least 1 area of cancer that the doctor can measure on a scan and is a certain size or bigger.And the doctors know whether your cancer has a certain biomarker called TROP2. You have NSCLC that has a certain amount of the protein PD-L1.There is a tissue sample ( biopsy ) of your cancer that the team can access.Or you have NSCLC that has spread to another part of the body ( stage 4). You have non small cell lung cancer (NSCLC) that has spread into the nearby tissue ( stage 3B or 3C) and cannot be removed by surgery or treated with chemoradiotherapy.You may be able to join this trial if all of the following apply. Talk to your doctor or the trial team if you are unsure about any of these. The following bullet points are a summary of the entry conditions for this trial. how the combination affects quality of life.more about the side effects of this combination.how well the combination of Dato-DXd, durvalumab and carboplatin works for people with advanced NSCLC.Researchers think that the combination of Dato-DXd, durvalumab and carboplatin could be better than the pembrolizumab and chemotherapy. It then releases the deruxtecan into the cancer cell damaging or killing the cell. It has two parts, they are:ĭatopotamab finds a protein called TROP2 on the cancer cell. It also works by helping the immune system to find, recognise and kill cancer cells.ĭatopotamab deruxtecan (Dato-DXd) is a type of drug called an antibody drug conjugate. It works by helping the immune system to find, recognise and kill cancer cells.ĭurvalumab is another type of immunotherapy drug. They kill cancer cells by stopping them from dividing and growing. Paclitaxel, carboplatin, pemetrexed and cisplatin are chemotherapy drugs. They can also teat advanced NSCLC with durvalumab after having had chemoradiotherapy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |